Nimodipine is a highly lipophilic, centrally acting calcium channel blocker. It is similar in action to flunarizine, which has been studied for use in the medical treatment of Meniere's disease.
Nimodipine was offered to patients with Meniere's disease for whom first-line medical management failed (dietary restrictions and diuretics or vestibular suppressants).
Our preliminary clinical experience using nimodipine in 12 patients with Meniere's disease from December 1992 until March 1995 resulted in successful control of vertigo and hearing improvement or stabilization in seven (58%) of 12 patients. When hearing stabilization was not considered, eight (67%) patients had vertigo satisfactorily controlled (AAOO class A, B, or C). The four (33%) patients whose vertigo symptoms persisted despite treatment with nimodipine (AAOO class D) were surgically treated with successful vertigo control. Nimodipine was discontinued in one class D patient because of gastrointestinal intolerance.
Nimodipine provides an alternative successful means for medical management of Meniere's disease.
© 1996, The American Journal of Otology, Inc.